Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.
The Mitogen Activated Protein Kinase (MAPK) pathway plays a key role in melanoma development making it an important therapeutic target. In normal cells, the tightly regulated pathway relays extracellular signals from cell membrane to nucleus via a cascade of phosphorylation events. In melanomas, dysregulation of the MAPK pathway occurs frequently due to activating mutations in the B-RAF and RAS genes or other genetic or epigenetic modifications, leading to increased signaling activity promoting cell proliferation, invasion, metastasis, migration, survival and angiogenesis. However, identification of ideal pathway member to therapeutically target for maximal clinical benefit to melanoma patients remains a challenge. This review provides an overview of the obstacles faced targeting the MAPK pathway and why certain therapeutic approaches succeed while others fail. The review summarizes the roles played by the proteins, therapeutic potential and the drugs available to target each member of the pathway as well as concerns related to each. Potential for targeting multiple points and inhibiting other pathways along with MAPK inhibition for optimal efficacy are discussed along with explanations for development of drug resistance, which includes discussions related to cross-talk between pathways, RAF kinase isoform switching and phosphatase deregulation. Finally, the use of nanotechnology is reviewed as an approach to target the MAPK pathway using both genetic and pharmacological agents simultaneously targeting multiple points in the pathway or in combination with other cascades.
Inamdar
Gajanan S
GS
Departments of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, United States.
Madhunapantula
SubbaRao V
SV
Robertson
Gavin P
GP
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D020935:MAP Kinase Signaling System; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000187:drug effects; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
J Natl Cancer Inst. 2010 Feb 24;102(4):214-5
20145213
Cancer Res. 2004 Aug 15;64(16):5556-9
15313890
Nature. 2006 Jan 19;439(7074):358-62
16273091
J Cell Biochem. 2006 Apr 15;97(6):1184-90
16440317
Nanomedicine. 2005 Mar;1(1):22-30
17292054
Cancer Res. 2004 Apr 1;64(7):2338-42
15059882
Curr Biol. 2005 Feb 8;15(3):249-54
15694309
Cancer Res. 2008 Jun 15;68(12):4853-61
18559533
J Clin Oncol. 2008 May 1;26(13):2178-85
18445842
Mol Cancer Ther. 2006 Dec;5(12):3071-7
17172409
Nat Rev Drug Discov. 2006 Oct;5(10):835-44
17016424
Curr Opin Investig Drugs. 2007 Jun;8(6):452-6
17621874
Melanoma Res. 2001 Feb;11(1):75-81
11254118
Cancer Res. 2007 Jun 15;67(12):5814-20
17575149
Biochem Biophys Res Commun. 2008 Jun 6;370(3):509-13
18402768
Clin Cancer Res. 2008 Jan 1;14(1):230-9
18172275
Mol Cancer Ther. 2008 Sep;7(9):2876-83
18790768
Cancer Invest. 2010 May;28(4):350-6
19968499
Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix
19464601
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2376s-2383s
16609062
PLoS One. 2009 May 27;4(5):e5717
19492075
Expert Opin Investig Drugs. 2001 Dec;10(12):2105-16
11772308
Arch Immunol Ther Exp (Warsz). 2007 Nov-Dec;55(6):363-72
18060370
Cancer Res. 2005 May 15;65(10):4005-11
15899789
Clin Cancer Res. 2009 Mar 1;15(5):1674-85
19208796
FASEB J. 2008 Apr;22(4):954-65
18039929
Oncogene. 2006 Oct 12;25(47):6262-76
16702958
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2366s-2370s
16609060
Br J Dermatol. 2007 Jun;156(6):1204-13
17388918
Nature. 2005 Aug 4;436(7051):720-4
16079850
Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):28-35
19149686
J Dermatol Sci. 2007 Apr;46(1):11-20
17267180
Front Biosci. 2005 Sep 01;10:2986-3001
15970553
Genes Dev. 1997 Nov 1;11(21):2822-34
9353252
Cancer Lett. 2002 May 28;179(2):133-40
11888667
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
J Biol Chem. 2000 Sep 1;275(35):27354-9
10869359
Int J Cancer. 2003 Jun 10;105(2):165-75
12673674
Mol Cell. 2009 Nov 13;36(3):477-86
19917255
Biochim Biophys Acta. 2003 Jun 5;1653(1):25-40
12781369
Pigment Cell Melanoma Res. 2010 Feb;23(1):93-102
19895547
Mol Cancer Ther. 2010 Jan;9(1):134-44
20053779
Br J Cancer. 2006 Sep 4;95(5):581-6
16880785
Pigment Cell Melanoma Res. 2010 Apr;23(2):190-200
20149136
J Clin Oncol. 2008 May 1;26(13):2139-46
18390968
Onkologie. 2004 Dec;27(6):540-4
15591712
Clin Cancer Res. 2001 Jul;7(7):2016-21
11448919
Expert Rev Anticancer Ther. 2007 May;7(5):617-26
17492926
Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85
15520807
Cancer Res. 2006 Oct 1;66(19):9483-91
17018604
Expert Opin Emerg Drugs. 2009 Dec;14(4):633-48
19715444
J Invest Dermatol. 2008 Aug;128(8):2013-23
18323781
Nature. 1999 Jul 29;400(6743):468-72
10440378
Cancer Res. 2003 Feb 15;63(4):756-9
12591721
Pigment Cell Melanoma Res. 2009 Aug;22(4):400-19
19493313
Cancer Cell. 2004 Oct;6(4):313-9
15488754
Oncogene. 2007 May 14;26(22):3291-310
17496923
Cancer J Sci Am. 2000 Feb;6 Suppl 1:S99-103
10685668
Rev Recent Clin Trials. 2007 May;2(2):121-34
18473997
Methods Enzymol. 2008;439:25-38
18374154
Am J Pathol. 2009 Jun;174(6):2367-77
19389934
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2371s-2375s
16609061
Neoplasia. 2009 Aug;11(8):720-31
19649202
Br J Dermatol. 2010 Mar;162(3):677-80
19919630
Cancer Chemother Pharmacol. 2008 Apr;61(4):535-48
18026728
J Natl Cancer Inst. 2003 Dec 17;95(24):1878-90
14679157
Br J Cancer. 2009 Nov 17;101(10):1724-30
19861964
Cancer Lett. 2009 Oct 8;283(2):125-34
19217204
Clin Cancer Res. 2003 Aug 15;9(9):3362-8
12960123
Prog Cell Cycle Res. 2003;5:219-24
14593716
J Invest Dermatol. 2009 Feb;129(2):383-91
18754039
J Clin Oncol. 2009 Jun 10;27(17):2823-30
19349552
J Natl Cancer Inst. 2001 May 2;93(9):678-83
11333289
Cancer Res. 2001 Jan 1;61(1):131-7
11196150
Neuro Endocrinol Lett. 2002 Jul;23 Suppl 2:48-51
12163848
J Transl Med. 2012 Dec 10;10:246
23228035
J Dtsch Dermatol Ges. 2006 Mar;4(3):205-17
16626317
Curr Top Med Chem. 2007;7(14):1364-78
17692026
Nature. 2002 Jun 27;417(6892):949-54
12068308
Oncogene. 2004 Aug 19;23(37):6292-8
15208680
Cancer Res. 2006 Aug 15;66(16):8200-9
16912199
Pigment Cell Melanoma Res. 2009 Aug;22(4):388-99
19493316
Semin Cutan Med Surg. 2009 Jun;28(2):96-102
19608060
Cancer Res. 2000 Apr 1;60(7):1800-4
10766161
Oncogene. 2001 Nov 15;20(52):7658-67
11753643
Proc Natl Acad Sci U S A. 2009 May 12;106(19):7957-61
19383798
J Biol Chem. 2010 Jan 1;285(1):242-54
19880519
Oncogene. 2010 Apr 22;29(16):2449-56
20118982
J Invest Dermatol. 2007 Sep;127(9):2207-15
17508026
Cancer Res. 2006 Jan 15;66(2):999-1006
16424035
Oncogene. 2008 Feb 7;27(7):877-95
17724477
J Invest Dermatol. 2006 Jan;126(1):154-60
16417231
Clin Cancer Res. 2008 Aug 1;14(15):4836-42
18676756
Nature. 2010 Mar 18;464(7287):427-30
20179705
Nature. 2010 Apr 15;464(7291):1067-70
20305636
Oncology. 2000 Feb;58(2):89-95
10705235
Cancer Cell. 2009 Apr 7;15(4):294-303
19345328
Int J Oncol. 2009 Jun;34(6):1481-9
19424565
Cancer Res. 2001 Oct 15;61(20):7507-17
11606387
Am J Ther. 2003 May-Jun;10(3):203-10
12756427
Cell. 2010 Jan 22;140(2):209-21
20141835
Cancer Res. 2005 Mar 15;65(6):2412-21
15781657
Cell. 2004 Mar 19;116(6):855-67
15035987
Curr Oncol Rep. 2006 Sep;8(5):400-5
16901402
Onkologie. 2005 Feb;28(2):101-7
15665559
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6
18287029
Nature. 2009 Sep 24;461(7263):542-5
19727074
J Clin Pathol. 2005 Nov;58(11):1163-9
16254105
J Invest Dermatol. 2008 Aug;128(8):2003-12
18323787
J Clin Oncol. 2005 Aug 10;23(23):5281-93
16009947
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6
19915144
Cancer Res. 2008 Sep 15;68(18):7638-49
18794153
APMIS. 2007 Oct;115(10):1161-76
18042149
Nature. 2010 Mar 18;464(7287):431-5
20130576
Mol Cancer Ther. 2007 Aug;6(8):2209-19
17699718
Br J Cancer. 2007 Feb 12;96(3):445-9
17245336
Purinergic Signal. 2006 Nov;2(4):627-32
18404465
Cancer Cell. 2007 May;11(5):447-60
17482134
Cell. 2008 Feb 8;132(3):363-74
18267069
Cancer Res. 2008 Jan 1;68(1):5-8
18172288
Expert Rev Anticancer Ther. 2008 Apr;8(4):553-60
18402522
Cancer Cell. 2003 Aug;4(2):95-8
12957284
J Invest Dermatol. 2003 Jan;120(1):109-15
12535206
Photochem Photobiol. 2008 Mar-Apr;84(2):289-306
18086245
Semin Oncol. 2006 Aug;33(4):392-406
16890795
J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74
11459867
Neoplasia. 2008 Nov;10(11):1231-9
18953432
Mol Cell Biol. 2010 Feb;30(3):806-19
19933846
Cancer Res. 2004 Oct 1;64(19):7099-109
15466206
Expert Rev Anticancer Ther. 2006 Jan;6(1):121-30
16375649
J Clin Endocrinol Metab. 2007 Dec;92(12):4712-8
17878251
Clin Cancer Res. 2008 Jun 1;14(11):3571-81
18519791
Cancer Res. 2007 Oct 15;67(20):9750-61
17942905
Expert Opin Investig Drugs. 2003 Mar;12(3):413-21
12605564
Melanoma Res. 2001 Feb;11(1):11-9
11254111
Cancer Res. 2008 May 1;68(9):3429-39
18451171
J Am Chem Soc. 2001 Mar 7;123(9):2107-8
11456854
Mol Cancer Ther. 2006 May;5(5):1136-44
16731745
Oncogene. 2009 Jan 8;28(1):85-94
18794803
Nat Genet. 2009 May;41(5):544-52
19282848
Br J Cancer. 2009 Feb 10;100(3):431-5
19156138